Epidermal growth factor receptor (EGFR) stimulates proliferative and survival signals. Activating mutations of EGFR are involved in the aetiology and maintenance of the malignant phenotype of lung tumours. We previously described the frequent association of these mutations with the decreased expression of the p14 ARF tumour suppressor, another common feature of lung cancer. Based on these data, we postulated that p14 ARF could protect cells against untimely or excessive mitotic signals induced by mutant EGFR. In this study, we demonstrate that p14 ARF promotes apoptosis in lung tumour cells harbouring the EGFR L858R mutation through the accumulation of phosphorylated signal transducer and activator of transcription 3 (STAT3) on Tyr 705 residue, which leads to Bcl-2 downregulation. Using siRNA against PTP-RT, the phosphatase that specifically targets Tyr 705 residue, we show that accumulation of pSTAT3-Tyr705 promotes EGFR L858R mutant cell death, thereby confirming the existence of a STAT3-dependent pro-apoptotic pathway in these cells. Finally, we show that the expression of the EGFR L858R mutant represses p14 ARF expression and inhibits STAT3/Bcl-2 signalling. These results identify a novel link between the p14 ARF and EGFR pathways and suggest that EGFR L858R counteracts the pro-apoptotic function of p14 ARF by downregulating its expression to promote carcinogenesis.
INTRODUCTION
Epidermal growth factor receptor (EGFR) is a membrane-bound receptor tyrosine kinase that belongs to the ErbB subfamily. 1 Upon ligand binding, EGFR initiates activation of a series of cellular signal transduction pathways that regulate proliferation and survival. 2 --4 In agreement with an oncogenic role of EGFR, increased levels of EGFR gene expression are observed in a variety of human cancers, including carcinoma of the lung, in which EGFR overexpression is correlated with a poor prognosis. 5 --8 Somatic-activating mutations in the tyrosine kinase domain of EGFR are also observed in lung adenocarcinomas and are associated with a high likelihood of clinical response to treatment with EGFR tyrosine kinase inhibitors. 9 --11 Most lung adenocarcinomaassociated somatic mutations are represented by the in-frame deletion of amino acids 47 --750 in exon 19 (Del19) and the missense substitution L858R in exon 21 (L858R). 12 These kinase domain mutations in EGFR are generally referred to as activating mutations, as they result in the increased activity of the receptor, leading to the hyperactivation of downstream pro-survival pathways (PI3K/AKT, STAT) and oncogenic transformation (RAS/ MAPK). 13 --15 Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is important in mediating the pro-survival effects of mutant EGFR.
2 STAT3 becomes activated through the phosphorylation of tyrosine residue 705 by Janus kinases in response to cytokine signalling or by receptors with intrinsic tyrosine kinase activity, such as EGFR. 16 Phosphorylation results in dimerisation and translocation of STAT3 to the nucleus, where it activates transcription of a wide variety of genes involved in cell growth and survival. 17 --19 STAT3 is transiently activated in normal cells but is constitutively activated in lung adenocarcinoma cells expressing activating mutant EGFR. 20, 21 The p14 ARF protein (p14 ARF in humans and p19 ARF in mice) is encoded in the INK4a/ARF locus, together with p16 INK4a . 22 p14
ARF is a nuclear protein with tumour suppressor activity and is a key component of major signalling pathways that are responsible for restraining abnormal cell growth and for maintaining genomic stability in response to DNA damage and oncogenic stress. ARF also displays inhibitory cell growth control independently of p53. 23, 24 Therefore, p14 ARF is a critical component of tumour surveillance and has a strong protective role against lung cancer development. 25 It has been shown that p14 ARF expression is frequently downregulated in human lung cancer, especially in small cell lung cancer and lung adenocarcinoma. 26 --28 More recently, we observed that nearly all lung adenocarcinoma with EGFR L858R-or Del 19-activating mutations have low or undetectable levels of p14 ARF protein, 29 suggesting that p14 ARF could be part of a failsafe mechanism protecting cells against untimely or excessive mitotic signals induced by EGFR signalling.
In agreement with such a role, we report here that p14 ARF inhibits the proliferation of EGFR L858R mutant cells by inducing cell death. This process involves the activation of a STAT3-dependent pro-apoptotic signalling pathway aimed at restraining the expression of Bcl-2. Furthermore, we show that EGFR L858R inhibits p14 ARF expression and in this way counteracts the pro-apoptotic p14 ARF /STAT3 pathway. These results provide the first evidence of cross talk between the p14 ARF and mutant EGFR pathways.
RESULTS

Expression of p14
ARF promotes apoptosis in EGFR L858R mutant cells To study the existence of a potential interplay between p14 ARF and EGFR, we first performed a western blot analysis of p14 ARF expression in a panel of lung cancer cell lines with different EGFR/ Her2 status. As illustrated in Figure 1a , a strong variation of p14 ARF expression levels was observed among the cell lines. However, and in agreement with our previous findings in lung primary tumours, 29 a low level of p14 ARF was more frequently observed in cell lines with mutant EGFR. To investigate the relationships linking p14
ARF and mutant EGFR, we choose two representative cell lines carrying the EGFR L858R mutation and expressing low level of p14 ARF , the H1975 and H3255 cell lines. H1975 cells were transfected with an expression vector encoding the human p14 ARF protein and stained with trypan blue to evaluate cell number. As H1975 cells are difficult to transfect, they were selected with geneticin (G418) in the culture medium for 6 days before staining. We observed a 60% decrease in cell number upon p14 ARF transfection compared with the cells transfected with a control empty vector (Figure 1b) . Cell cycle profiling of p14 ARF -transfected cells failed to detect any significant changes in G1/S/G2 phase distribution (data not shown). In contrast, active caspase3 staining in p14
ARF -transfected cells clearly revealed apoptosis 72 h post-transfection (Figure 1c) . Although H1975 cells express a very low level of p14 ARF , its depletion using specific siRNA promoted the proliferation of EGFR L858R mutant cells compared to control mismatch siRNA (Figure 1d ). Similar results were obtained in H3255 cells (Supplementary Figure S1) . These results indicate that p14 ARF inhibits the proliferation of EGFR L858R mutant cells by inducing apoptosis.
p14
ARF -mediated apoptosis involves the accumulation of pSTAT3-Y705 PI3K/Akt, Jak/STAT and MEK/ERK are key signal transduction pathways activated by EGFR.
2 Therefore, we studied the status of AKT, STAT3/5 and ERK proteins in response to p14
ARF . H1975 cells were transfected with either control or p14 ARF encoding expression vectors, and western blot analyses were performed after 6 days of G418 selection. We observed that the expression of p14 ARF was associated with the accumulation of phosphorylated STAT3 at residue Y705 (pSTAT3-Y705) (Figure 2a ). In contrast, no apparent modification of STAT5, AKT or ERK status was found in the same conditions. To add further evidence that p14
ARF promotes the accumulation of pSTAT3-Y705, H1975 cells were transiently transfected with an empty vector or with a p14 ARF encoding vector, and 48 h post-transfection the expression level of phosphorylated STAT3 was evaluated by pSTAT3-Y705 staining in p14 ARF -transfected cells followed by FACS analysis. Again, a higher level of pSTAT3-Y705 was found in p14
ARF -transfected cells compared with the control-transfected cells (Figure 2b ). Conversely, a strong downregulation of pSTAT3-Y705 expression was ARF controls EGFR L858R signalling P Ozenne et al observed when H1975 cells were deprived of p14 ARF by siRNA treatment (Figure 2c ). Similar accumulation of pSTAT3-Y705 by p14 ARF was found when using the H3255 model (Supplementary Figure S2) . When activated by tyrosine kinase signals, pSTAT3 accumulates in the nucleus to regulate gene expression. 19 Using immunofluorescence staining, we observed that the transfection of p14 ARF induced the nuclear accumulation of pSTAT3-Y705 ( Figure 2d ). To analyse whether accumulation of pSTAT3-Y705 was indeed involved in p14
ARF -mediated apoptosis, we neutralised the STAT3 pathway by treating H1975 cells transfected with either control or p14 ARF expression vector with the specific STAT3 pharmacological inhibitor cucurbitacin I. Cucurbitacin I strongly inhibited STAT3 phosphorylation in these cells (Figure 2e lower panel) and more importantly prevented apoptosis in p14 ARFtransfected cells compared to non-treated cells (Figure 2e upper panel). Of note, a slight downregulation of STAT3 expression was found in the presence of cucurbitacin I in agreement with autoregulation of the STAT3 gene. 30, 31 Furthermore, decreased p14 ARF expression protein levels were reproducibly observed in response to cucurbitacin I, suggesting the existence of a positive feedback loop between p14 ARF and STAT3. We concluded that the activation of STAT3 is critical for p14 ARF -mediated apoptosis in EGFR mutant L858R cells. As these data implied that pSTAT3-Y705 promotes apoptosis in our L858R mutant models, H1975 and H3255 cells were transfected with siRNA against PTP-RT, a phosphatase that specifically dephosphorylates STAT3 on Tyr 705. 32 As illustrated, silencing PTP-RT resulted in the accumulation of pSTAT3-Y705 ( Figure 3a ) and strongly promoted cell death, as measured by caspase 3 cleavage (Figures 3a and b) . Importantly, treating PTP-RT knockdown cells with cucurbitacin I significantly prevented the induction of apoptosis, thereby demonstrating that pSTAT3-Y705 is the main target of PTP-RT in that case (Figure 3c ). Altogether, these data support the idea that STAT3 activates an intrinsic pro-apoptotic signalling pathway in lung tumour cells harbouring the EGFR L858R mutation and indicate that p14 ARF activates this pathway.
The pro-apoptotic p14 ARF /STAT3 signalling pathway targets Bcl-2
Phosphorylation at tyrosine 705 is critical for the activation of STAT3 signal transduction. 19 Numerous STAT3 target genes have been identified and include regulators of apoptosis such as Bcl-xL, Bcl-2 and Bax. 21, 33 In our cellular models expressing mutant EGFR L858R, inhibiting STAT3 expression (Figure 4a Figure S2) . In both cases, a significant deregulation of Bcl-2 transcripts was also observed (data not shown). In addition, treating cells with cucurbitacin I prevented the downregulation of Bcl-2 induced by p14 ARF (Figure 4e ). Overall, these data identified Bcl-2 as an important target of the STAT3-dependent pro-apoptotic signalling pathway in EGFR L858R cells and indicated that p14 ARF triggers STAT3-dependent downregulation of Bcl-2 expression.
The EGFR L858R mutant downregulates p14 ARF expression and counteracts the p14 ARF /STAT3 pro-apoptotic pathway
We previously observed that p14 ARF levels are very low in human lung tumours with activating mutant EGFR, 29 as well as in the H1975 and H3255 lung tumour cell lines (Figure 1a) . Therefore, we postulated that the EGFR L858R mutant might inhibit p14 ARF expression to counteract its pro-apoptotic function. We first transfected H1299 lung adenocarcinoma cells with a plasmid encoding the EGFR L858R mutant and analysed the expression of endogenous p14 ARF either by immunofluorescence staining 2 days post-transfection (Figure 5a ) or by western blotting after 6 days of G418 selection (Figure 5b) . In both situations, a significant downregulation of p14 ARF protein was observed in cells expressing the EGFR L858R mutant. Conversely, silencing EGFR L858R in both H1975 and H3255 cells induced the accumulation of p14 ARF (Figure 5c ). In order to confirm the effect of activated EGFR on p14 ARF expression, we used the H1719 cell line that expresses wild-type EGFR. Treating cells with EGF induced accumulation of phosphorylated EGFR (Figure 5d, lower panel) 
ARF expression. Finally, we investigated the consequences of p14 ARF modulation in response to EGFR activation. Consistent with the hypothesis that EGFR L858R represses the proapoptotic p14
ARF /STAT3/Bcl-2 signalling pathway, the downregulation of p14 ARF expression following transfection of H1299 cells with EGFR L858R expression vector was accompanied by reduced levels of pSTAT3-Y705 as well as an upregulation of Bcl-2 expression (Figure 6a) . Conversely, accumulation of pSTAT3-Y705 and downregulation of Bcl-2 were observed in EGFR L858R-depleted cells (Figure 6b ) and correlated with an induction of apoptosis ( Figure 6c ) and inhibition of cell proliferation (Figure 6d) . Importantly, silencing p14 ARF rescued EGFR L858R knockdown cells from pSTAT3-Y705 accumulation and Bcl-2 downregulation (Figure 6b ), from induction of apoptosis (Figure 6c ) and from inhibition of cell proliferation (Figure 6d ). These results demonstrate that the EGFR L858R mutant counteracts the p14 ARF / STAT3/Bcl-2-dependent pro-apoptotic signalling pathway by a mechanism involving the downregulation of p14 ARF DISCUSSION Somatic-activating mutations in the tyrosine kinase domain of EGFR are involved in the aetiology and maintenance of lung tumours through constitutive activation of AKT and STAT survival pathways. Recently, reduced levels of p14 ARF were observed in almost all lung tumours harbouring activating mutant EGFR, suggesting a role for the p14 ARF tumour suppressor in the control of mutant EGFR signalling. Here, we demonstrate that p14 ARF is a potent growth inhibitor of lung tumour cells expressing the EGFR L858R-activating mutation and promotes cell death by activating a pro-apoptotic STAT3 pathway. In addition, we show that the EGFR L858R mutant counteracts the anti-proliferative function of p14 ARF by repressing its expression and STAT3-dependent pro-apoptotic signalling. These results identify a novel cross talk between the p14 ARF and EGFR pathways and suggest that inactivation of p14 ARF cooperates with activated EGFR to promote lung tumourigenesis. We show that transient expression of p14 ARF induces apoptosis in EGFR L858R mutant cells and that STAT3 is an important factor in signalling p14 ARF -mediated cell death. STAT3 activation has been associated with proliferation, survival and cellular transformation. However, there are a number of examples where activated STAT3 appears to have a role in the differentiation and in promoting apoptosis. 34 --37 In one such example, STAT3 activation has an established pro-apoptotic role during involution of the mammary gland. 37 In this study, we show that blocking STAT3 activation prevents ARF-mediated apoptosis. This suggests that a pro-apoptotic STAT3 signalling pathway contributes to growth inhibition of EGFR L858R mutant cells by p14
ARF . In addition, we demonstrate that activated pSTAT3-Y705 accumulates in p14 ARF -transfected cells and promotes the downregulation of Bcl-2 expression. These results suggest that p14 ARF represses p14 ARF controls EGFR L858R signalling P Ozenne et al the transcriptional activity of STAT3 towards Bcl-2. It has been reported that Tip60 controls the transcriptional activity of STAT3. 38 Moreover, we previously reported that p14 ARF interacts with Tip60 and controls its ability to regulate gene expression. 39 It is tempting to speculate that Tip60 has a role in STAT3-mediated repression of Bcl-2 expression by p14 ARF . Interestingly, depleting Tip60 using siRNA in H1975 cells resulted in the deregulation of pSTAT3-Y705 and Bcl-2 expression (data not shown). Further experiments are required to decipher the mechanisms involved in the control of STAT3 activity by Tip60 and to address the role of p14 ARF in this context. Constitutive activation of AKT and STAT survival pathways correlates with oncogenic activity of mutant EGFRs. 13, 15 In this respect, mutant EGFRs have been reported to mediate indirect activation of a proliferative IL-6/gp130/JAK/STAT3 pathway, and high levels of activated STAT3 are observed in lung adenocarcinoma harbouring activating mutations of EGFR. 40 Conversely, expression of mutant EGFRs appears essential for suppression of pro-apoptotic signals in lung cancers harbouring these mutations, as their neutralisation results in rapid apoptosis. 13, 15 However, the mechanisms and targets involved in this process are largely unknown. In this study, we show that a STAT3-dependent signalling pathway has a role in promoting apoptosis in EGFR L858R mutant cells and that the p14 ARF tumour suppressor activates this pathway. We also provide evidence that the EGFR (c) H1975 cells were transfected with either control (Ctl) or siRNA against PTP-RT for 48 h and incubated with Cucurbitacin I (2 mM) for additional 24 h. Total cellular extracts were subjected to western blot analysis with indicated antibodies. Tubulin was used as a loading control. Apoptosis was evaluated by active caspase 3 staining, followed by FACS analysis. Relative levels of apoptotic cells were calculated as described below.
p14 ARF controls EGFR L858R signalling P Ozenne et al L858R mutant downregulates p14 ARF expression and therefore inhibits this STAT3-dependent pro-apoptotic signalling. These data indicate that p14 ARF is part of a failsafe mechanism protecting cells against untimely or excessive mitotic signals induced by EGFR L858R signalling and that inactivation of the ARF/STAT3 proapoptotic pathway contributes to mutant EGFR L858R dependence. This could explain the high frequency of decreased p14 ARF expression in tumours harbouring an L858R mutation in the EGFR kinase domain. 29 Interestingly, our results strongly suggest that STAT3 positively regulates p14 ARF expression identifying a positive feed-back loop between both proteins. Further experiments are required to elucidate whether STAT3 has a role in the control of p14 ARF expression by the EGFR L858R mutant. Identifying the regulatory pathways that affect the oncogenic potential of mutant EGFRs could contribute to the development of targeted therapies in the treatment of lung cancer. We demonstrate that p14 ARF promotes apoptosis of cells harbouring the EGFR L858R mutation by inducing a STAT3/Bcl-2 pro-apoptotic pathway. Interestingly, these data are also observed in the H1975 cell line that carries a T790M drug resistant mutation in addition to the exon 21 substitution mutation. Therefore, manipulation of the p14 ARF /STAT3 pathway might provide an additional therapeutic strategy in conjunction with EGFR-TKI and BH3 mimetics to enhance the death of cells that depend upon mutant EGFR-L858R signalling for survival, but also to overcome resistance of T790M-containing tumours.
MATERIALS AND METHODS
Cell lines, treatments, plasmids and transfection
Calu3, A549, H358, H1299, HCC1719, H1975, H3255, H1650 and HCC827 cell lines were derived from human lung adenocarcinoma. HBECK3KT cells were immortalised human bronchial epithelial cells. Calu3, A549, H1299, H358 and HCC1719 cells carry a wild-type EGFR, H1975 and H3255 cells harbour a missense substitution L858R in exon 21, and H1650 and HCC827 have an E746_A750 deletion in exon 19. H1975 cells also carry a T790M mutation. All cell lines were cultured in 5% CO 2 at 37 1C in RPMI-1640 medium (GIBCO, Cergy Pontoise, France). Transient transfections were carried out using JetPEI (Ozyme, Saint Quentin Yvelines, France) according to the manufacturer's instructions. In the growth suppression assay and associated western blot analyses, G418 (Geneticin, PAA, Pashing, Austria) was added to the media 48 h post-transfection and cells were maintained for 6 days to select vector-transfected clones. Trypan blue excluding cells were counted and total protein extracts were performed for western blot analyses. Plasmids used in transient transfections were pcDNA3.1 (used as a control), pcDNA3.1-p14 ARF and pcDNA3.1-EGFR-L858R. Treatment with 2 mM cucurbitacin I (sc-203010, Santa Cruz, TEBU, Le Perray en Yvelines, France) was carried out for 24 h. For EGF treatment, cells were incubated in serum-free medium for 24 h. After medium change, EGF (50 ng/ml) was added for 24 h.
Transfection of siRNA oligonucleotides
The sequences designed to specifically target human p14 ARF PTP-RT and EGFR RNAs were as follows: p14 
Western blot experiments and antibodies
Immunoblotting was performed using whole-cell extracts prepared in RIPA buffer, as described previously. 25 The anti-EGFR, anti-HER2/ErbB2 (M45), anti-STAT3 (79D7), anti-pSTAT3-Y705 (D3A7), anti-STAT5 (3H7), antipSTAT5-Y694, anti-AKT (C67E7), anti-pAKT-S473, anti-ERK1/2, anti-pERK1/ 2-Y202/204 (E10) and anti-cleaved caspase3 (Asp175) antibodies were purchased from Cell Signalling (Ozyme, Saint Quentin Yvelines, France). The anti-Bcl-2 (C-2), anti-Bcl-xL (H62), anti-Bax (N20) and anti-tubulin (B5-1-2) antibodies were purchased from Santa Cruz. The anti-p14 ARF (Ab1) antibody was from Calbiochem (VWR, Fontenay-sous-Bois, France) and the anti-Actin antibody was purchased from Sigma (Saint Quentin Fallavier, France).
Indirect immunofluorescence
For immunolocalisation studies, cells were fixed with 2% paraformaldehyde in PBS for 10 min at room temperature, washed once with PBS and permeabilised with 0.1% Triton X-100 in PBS for 10 min. Blocking was performed for 45 min in 5% BSA and incubation with anti-p14 ARF (Ab2) 
Quantitative RT--PCR analysis
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Courtaboeuf, France) and subjected to quantitative RT--PCR, as described previously. 41 The primers used for mRNA amplification were as follows: PTP-RT forward: ARF (green) and EGFR L858R (red) was analysed by immunofluorescence using anti-p14 ARF and anti-phospho EGFR antibodies, respectively. DAPI (blue) was used to counterstain nuclei. (b) H1299 cells were transfected with either control (Ctl) empty vector or EGFR L858R expression vector and selected for 6 days with G418. Total cellular extracts were subjected to western blot analysis with indicated antibodies. Actin was used as a loading control. The relative densitometric areas for p14 ARF were determined according to actin signal and arbitrarily assigned to 1 in control cells. (c) H1975 and H3255 cells were transfected with either control (Ctl) or EGFR siRNA for 72 h. Total cellular extracts were subjected to western blot analysis with indicated antibodies. Tubulin was used as a loading control. A relative p14 ARF /tubulin ratio was calculated as described below. (d) Total cellular extracts were prepared from unstimulated or EGF-stimulated H1719 cells for 24 h and subjected to western blot analysis with indicated antibodies. A 30-min EGF stimulation was performed to confirm EGFR activation. Tubulin was used as a loading control. A relative p14 ARF /tubulin ratio was calculated as described below.
p14 ARF controls EGFR L858R signalling P Ozenne et al expression was calculated for each sample as the ratio of target gene mRNA copy number to GAPDH mRNA copy number.
Apoptosis analysis
Induced apoptosis following neutralisation of EGFR was studied on a total cell population using the PE-conjugated monoclonal active caspase 3 antibody apoptosis kit (BD Biosciences, Pharmingen) according to the manufacturer's protocol. For the study of apoptosis following ARF transfection, a modified protocol was applied, allowing analysis of cells costained with ARF and active caspase 3 antibodies. In brief, cells were fixed with 0.5% paraformaldehyde for 5 min at 4 1C and subsequently permeabilised with 0.1% Triton X-100 in PBS for 5 min. Cells were blocked with 5% BSA for 30 min at room temperature. Cells were then incubated for 1 h with anti-p14 ARF antibody (Ab2, Calbiochem) in 1% BSA in PBS, washed twice with PBS and incubated for an additional 1 h with Alexa 488 and PE-conjugated active caspase 3 antibody (BD Biosciences, Pharmingen).
After being washed with PBS, cells were resuspended in PBS and subjected to flow cytometric analysis using a FACScan flow cytometer (BD Biosciences). Active caspase 3 staining was assessed on ARF stained cells. supported by AGIR à Dom. DD is supported by the Fond de dotation pour la recherche en santé respiratoire 2010. ARF controls EGFR L858R signalling P Ozenne et al
